With over €47,000 on the counter, Kiemeney can see the Tour de France as a great success. Not only did he get close to his target amount (you can still donate!), but Bart was also one of the few to have covered the entire course of this edition of the Tour de France.
"Now I'm really not going to cycle the Tour anymore!” the professor writes in his epilogue.
Bart's Tour de France
Read the entire epilogue on www.tourdefrancevanbart.nl or donate.That's still possible!


-
Want to know more about these subjects? Click on the buttons below for more news.
RIHSHealth EvidenceHealthcare improvement scienceUrology ResearchRare cancersTumors of the digestive tract Urological cancersWomen's cancers
Related news items

Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis
25 January 2021Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.
read more
Oral health research makes significant impact at the 148th WHO Executive Board meeting
25 January 2021During the 148th session of the World Health Organization (WHO) Executive Board meeting, Member States passed a game-changing resolution on oral health. WHO Director General Dr Tedros Adhanom Ghebreyesus called it a “landmark resolution”.
read more
Radboud Young Academy safeguards the future of science
21 January 2021New platform to provide advice on policy, create an interdisciplinary network of early career scientists, and promote career development.
read more
Increase radio- and immunotherapy efficacy by targeting hypoxia
21 January 2021In a paper recently accepted by Clinical Cancer Research, Daan Boreel, together with Paul Span, Sandra Heskamp, Gosse Adema and Jan Bussink, reviews the therapeutic potential of decreasing the lack of oxygen (hypoxia) often found in solid tumors.
read more
Radiation boost lowers risk of prostate cancer recurrence
21 January 2021An additional external-beam radiation dose delivered directly to the tumor can benefit the prospects of men with non-metastatic prostate cancer, without causing additional side effects. The risk of relapse within five years for these men is smaller than for men who did not receive this boost.
read more
New research through grants for Radboudumc researchers
14 January 2021Several researchers at the Radboudumc have received grants to start new studies, including on rare diseases, liver disease and cancer metastases. These are grants from the Dutch Research Council, European Joint Programme on Rare Diseases and the Gastric Liver Disease Foundation.
read more